Supplemental Agreement No. 3 - SENIORITY
Supplemental Agreement No. 2 This Supplemental Agreement No. 2 (this “Agreement”), entered into this fifth day of May, 2015, is made by and among Bacardi International Limited (“BIL”), Bacardi Corporation (“Corp”) and their parent company Bacardi Limited (“BL”) and the Government of Puerto Rico (the “Government”), acting through the Secretary of Treasury, the Secretary of Economic Development and Commerce, the Secretary of Agriculture, the President of the Government Development Bank for Puerto Rico, the Executive Director of the Office of Management and Budget and the Executive Director of the Puerto Rico Industrial Development Company (“PRIDCO”) as authorized by Act No. 178 of December 1, 2010, as amended, Act No. 1 of January 31, 2011 and any successor legislation (the “Enabling Act”). BIL, and any affiliate of BIL (including BL or Corp) that is designated by BIL to perform obligations under the applicable agreement, are collectively referred to as “Bacardi”. The Government, BIL, Corp and BL are collectively referred to as the “Parties” and each individually as a “Party”.
Supplemental Agreement No. 31 Boeing and Customer have been in discussions, among other things, about adjusting the [CONFIDENTIAL PORTION OMITTED AND FILED SEPARATELY WITH THE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT], the key elements of which are as set forth below:
Supplemental Agreement No. ⚫ to the GUARANTEE AND SUBORDINATION AGREEMENT (as hereinafter defined), entered into at ⚫, as of ⚫. AMONG: ⚫, as Guarantor AND: NATIONAL BANK OF CANADA, as Agent for the Lenders
Supplemental Agreement No. 1 to the GUARANTEE AND SUBORDINATION AGREEMENT (as hereinafter defined), entered into at Montreal , as of February 21, 2019. AMONG: SAPUTO DAIRY AUSTRALIA PTY LTD ABN 52 166 135 486, as Guarantor AND: NATIONAL BANK OF CANADA, as Agent for the Lenders
Supplemental Agreement No. 3 (exe) 11 9 COMMUNICATIONS The provisions of clause 17 of the Amended and Restated Loan Agreement shall apply to this Supplemental Agreement as if they were set out in full and as if references to "the Finance Documents" were references to this Supplemental Agreement and as if references therein to the "Borrowers" were references to all the parties to this Supplemental Agreement except for the Finance Parties. 10
Supplemental Agreement No. 8 to the Purchase Agreement provides for, in part, Customer’s exercise of its option to purchase six (6) Option Aircraft with delivery months as set forth below (SA-8 Early Exercise Aircraft) in advance of the Option Exercise Date for such Option Aircraft pursuant to the provisions of paragraph 6.1 of the reference (b) Letter Agreement (Early Exercise). Delivery Month & Year for SA-8 Early Exercise Aircraft [*] [*] [*] [*] [*] [*] * Blank spaces contained confidential information which has been filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 6-1162-LKJ-0728 SA-8 Special Matters – SA-8 Early Exercise Aircraft Page 1 BOEING PROPRIETARY
Supplemental Agreement No. 2 This Supplemental Agreement, made and entered into by and between XXXXXXX CONSULTANTS, INC. (Consultant) and CITY OF XXXX (Client) amends their agreement of July 12, 2016 for Consultant to provide services to the Client for the East Industrial Area Utility Extension Project, as follows: Scope of Services
Supplemental Agreement No. 1 TO CO-DEVELOPMENT AGREEMENT This Supplemental Agreement No. 1 to Co-Development Agreement (the “Supplement No.1”) is intended to supplement and be read together with that certain agreement titled the Co-Development Agreement by and between Acucela Inc. (“Acucela”) and Otsuka Pharmaceutical Co., Ltd. (“Otsuka”) of September 4, 2008 (the “Agreement”). This Supplement No. 1 is incorporated herein to the Agreement by this reference. Acucela intends to enter into that Clinical Study Agreements with approximately thirty five (35) institutions (the “Institutions”) related to the ACU-RED-301 study (the “CTAs”); Acucela provided the intellectual property rights clause and the publication clause from the CTA template to Otsuka for review and approval prior to finalizing the CTA template for use with the Institutions. Otsuka America Pharmaceutical, Inc. provided Acucela with written approval for both clauses in the CTA template on 03/22/2012; Acucela has the right to review and approve any proposed publication, presentation or manuscript (the “Proposed Publication”) pursuant to Article VII of the CTA template. Given that the CTA template is related to Otsuka compound known as Rebamipide which is the compound for the collaborative activities between Acucela and Otsuka under the Agreement, the parties hereby agrees:
Supplemental Agreement No. 7 (SA-7) to this Purchase Agreement is, in part, a reflection of [**].
